Neoadjuvant Treatment for Intermediate/High-Risk Her2-Positive and Triple-Negative Breast Cancers: No Longer an Option' but an Ethical Obligation
AuthID
P-00X-CPK
P-00X-CPK
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service